- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
March 29, 2018
On March 29, Dr. Zeda Rosenberg, International Partnership for Microbicides (IPM), and Dr. Jared Baeten, Microbicide Trials Network (MTN), presented on and discussed the latest data on the dapivirine vaginal ring for HIV prevention. Initial data from the HOPE and DREAM open-label extension ring trials were presented at CROI 2018 and showed that the use of the ring cut HIV risk by 50 percent. Learn more about what these initial data show us, what additional data are expected and plans for the ring in the coming year. And, as always, what can advocates do to advance the agenda?
Recording: YouTube / Audio / DREAM Slides / HOPE Slides